Literature DB >> 2323070

Non-M CK--a practical measure of creatine kinase isoenzymes in cancer patients.

P G McGing1, M Teeling, A McCann, F Kyne, D N Carney.   

Abstract

The individual creatinine kinase (CK) isoenzymes CK-BB and CK-Macro II have previously been investigated as potential tumour markers. We believe there is a need for a system to measure those CK forms not usually present in serum. We have studied a CK-MB immunoinhibition kit which measures all residual CK activity following inactivation of M-subunit activity. In 162 patients with cancer we found no difference in grading (+ or -) between detailed isoenzyme studies and the simple non-M assay. In 33 samples with elevated non-M CK, detailed analysis showed BB alone (45%), Macro II alone (9%), or both (36%). Raised activities were mainly found in patients with small cell lung cancer (SCLC) (17/40; 43%) and GI Tumours (6/11; 55%). In patients with SCLC, elevated activities were associated with disseminated disease. Preliminary evidence indicates that Non-M CK may also be a simple means of monitoring initial treatment response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323070     DOI: 10.1016/0009-8981(90)90116-a

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Inferior mesenteric venous sampling, pulse oximetry, and assessment of colonic perfusion during aortic aneurysm surgery.

Authors:  C P Delaney; N F Couse; D Mehigan; T V Keaveny
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

2.  Raised concentration of plasma creatine kinase BB isoenzyme in myelodysplasia.

Authors:  M Crook; A Williams; A Sankaralingam; P Tutt
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

3.  Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients.

Authors:  N Zarghami; M Giai; H Yu; R Roagna; R Ponzone; D Katsaros; P Sismondi; E P Diamandis
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.